share_log

Innate Pharma To Test Lacutamab In Relapsed/Refractory Peripheral T-Cell Lymphoma Patients

Innate Pharma To Test Lacutamab In Relapsed/Refractory Peripheral T-Cell Lymphoma Patients

先天藥物用於檢測復發/難治性外周T細胞淋巴瘤患者的Lacutamab
Benzinga Real-time News ·  2021/02/09 20:19
  • Innate Pharma SA's (NASDAQ: IPHA) ongoing TELLOMAK Phase 2 trial, evaluating lacutamab has reached the pre-determined number of responses needed to advance to stage 2, thus allowing Innate to recruit additional patients. The company expects to present the preliminary data from this cohort at a scientific meeting this year. The study is expected to recruit up to 150 patients.
  • Recruitment in cohort 3 is ongoing, evaluating lacutamab as monotherapy in KIR3DL2 non-expressing mycosis fungoides, the most common form of a type of blood cancer called cutaneous T-cell lymphoma.
  • The company also plans to initiate two parallel trials to evaluate lacutamab in KIR3DL2-expressing patients with relapsed/refractory peripheral T-cell lymphoma, including a Company-sponsored Phase 1b trial to evaluate lacutamab as monotherapy in KIR3DL2-expressing patients with relapsed PTCL, and an investigator-sponsored trial to evaluate lacutamab in combination with chemotherapy GEMOX, versus GEMOX alone in KIR3DL2-expressing relapsed/refractory patients.
  • Webcast and conference call is scheduled for 8:00 a.m. ET today.
  • Price Action: IPHA shares closed 5.5% higher at $4.63 on Monday.
  • 先天製藥公司(Innate Pharma SA)(納斯達克：IPHA)正在進行TELLOMAK第二階段試驗，評估lacutamab已經達到了進入第二階段所需的預定反應數量，從而允許Innate招募更多的患者。該公司預計將在今年的一次科學會議上公佈這一隊列的初步數據。這項研究預計將招募多達150名患者。
  • 在隊列3中的招募正在進行中，評估lacutamab作為KIR3DL2非表達真菌樣肉芽腫的單一療法，這是一種最常見的血癌類型，稱為皮膚T細胞淋巴瘤。
  • 該公司還計劃啟動兩個平行試驗為了評估lacutamab在表達KIR3DL2的複發性/難治性外周T細胞淋巴瘤患者中的作用，包括一項由公司贊助的1b期試驗，目的是評估lacutamab在表達KIR3DL2的複發性PTCL患者中作為單一療法的作用；以及一項由研究人員贊助的試驗，評估lacutamab聯合化療GEMOX，以及在表達KIR3DL2的復發/難治性患者中僅使用GEMOX的療效。
  • 網絡直播和電話會議安排在上午8：00。東部時間今天。
  • 價格行動：IPHA股價週一收高5.5%，報4.63美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論